Get the Stockscreener App
0.7683
0.99%
0.0075
After Hours:
.79
0.0217
+2.82%
Cognition Therapeutics Inc stock is traded at $0.7683, with a volume of 2.42M.
It is up +0.99% in the last 24 hours and up +2.44% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$0.7608
Open:
$0.778
24h Volume:
2.42M
Relative Volume:
0.34
Market Cap:
$31.92M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-0.9725
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
-2.26%
1M Performance:
+2.44%
6M Performance:
-30.15%
1Y Performance:
-67.31%
1-Day Range:
$0.71
$0.815
1-Week Range:
$0.696
$0.815
52-Week Range:
$0.34
$2.95
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2403 SIDNEY STREET, PITTSBURGH
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.7683 | 31.92M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
A Data-Based Look At Cognition Therapeutics Inc (CGTX) - Stocks Register
CGTXCognition Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine - GlobeNewswire
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy - The Bakersfield Californian
New Dementia Drug Achieves Remarkable 91% Reduction in Cognitive FluctuationsPhase 2 Results Revealed - StockTitan
Brokers Issue Forecasts for CGTX FY2024 Earnings - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Raised to “Strong-Buy” at Brookline Capital Management - Defense World
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - The Malaysian Reserve
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Alzheimer's Disease Clinical and Non-Clinical Studies, Key - openPR
**Cognition Therapeutics (NASDAQ:CGTX) Prepares to Advance Treatment Efforts** ** - Defense World
Dry Age Macular Degeneration Pipeline Insights 2024: Therapies, Clinical Trials, Therapies and Key Companies involved by DelveInsight |Janssen R&D, Belite Bio, Katairo, Cognition Therapeutics - Barchart
Dry Age Macular Degeneration Pipeline Insights 2024: - openPR
Cognition Therapeutics Shows Promising Phase 2 Study Results - TipRanks
Cognition Therapeutics Is Targeting A Critical Form Of Dementia - Nasdaq
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - The Manila Times
Cognition Therapeutics Advances DLB Treatment After Positive Phase 2 Results, CEO to Present at JPM Week - StockTitan
Cognition Therapeutics (NASDAQ:CGTX) versus Editas Medicine (NASDAQ:EDIT) Head-To-Head Contrast - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cognition Therapeutics Reports Promising Phase 2 Results for Dementia with Lewy Bodies Treatment - Citybuzz
Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial - Nasdaq
Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely - Simply Wall St
This Biotech Is Already Off To The Races Before The Opening Bell - MSN
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data - Yahoo Finance
Cognition Therapeutics Reveals Encouraging Results from Phase 2 COG1201 SHIMMER Study - Defense World
B. Riley Securities Upgrades Cognition Therapeutics (CGTX) - MSN
Cognition Therapeutics announces results in Phase 2 study of CT1812 - Yahoo Finance
H.C. Wainwright raises CGTX shares target, buy rating on trial results - Investing.com
TSX 60 Capped Index (TXCI) QuotePress Release - The Globe and Mail
Enhanced Cognition: Lewy body dementia phase II pumps stock - BioWorld Online
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
S&P 500 Health Care [Sector] (SRHC) QuotePress Release - The Globe and Mail
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday? - Benzinga
TSX Health Care Capped Index (TTHC) QuotePress Release - The Globe and Mail
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics, Inc. Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - Marketscreener.com
Cognition Therapeutics (NASDAQ:CGTX) Stock Quotes, Forecast and News Summary - Benzinga
Cognition Therapeutics Hopes To Affirm CT1812 Holds The Key To Slowing Progression Of Dementia With Lewy Bodies - Nasdaq
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024 - MSN
Cognition-Enhancing Drugs Market Innovations and Key Players: - openPR
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Yahoo Finance
HC Wainwright Has Negative Outlook of CGTX FY2024 Earnings - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.00 Consensus Price Target from Analysts - Defense World
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
HC Wainwright Reiterates “Buy” Rating for Cognition Therapeutics (NASDAQ:CGTX) - Defense World
What is B. Riley’s Estimate for CGTX FY2024 Earnings? - Defense World
Head to Head Comparison: Inhibrx (NASDAQ:INBX) and Cognition Therapeutics (NASDAQ:CGTX) - Defense World
What is B. Riley’s Estimate for CGTX FY2025 Earnings? - Defense World
Cognition Therapeutics concludes Phase 2 DLB study By Investing.com - Investing.com Canada
Cognition Therapeutics Announces all Participants have - GlobeNewswire
Cognition Therapeutics concludes Phase 2 DLB study - Investing.com
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):